NCT02456883View on ClinicalTrials.gov

Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 4, 2016

Primary Completion Date

May 20, 2017

Study Completion Date

June 19, 2017

Conditions
Advanced Solid TumorsPharmacokinetics of 14C-labeled Gilteritinib
Interventions
DRUG

gilteritinib

oral

DRUG

14C-labeled gilteritinib

oral

Trial Locations (1)

44195

Site US10001, Cleveland

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT02456883 - Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter